PYPD
PolyPid Ltd. Ordinary Shares
السعر في الوقت الحقيقي
مخطط الأسعار
المقاييس الرئيسية
مقاييس السوق
الافتتاح
$3.460
الأعلى
$3.460
الأدنى
$3.460
الحجم
0.25M
أساسيات الشركة
إحصاءات التداول
أخبار ذات صلة
HC Wainwright & Co. Maintains Buy on PolyPid, Raises Price Target to $13
HC Wainwright & Co. analyst Brandon Folkes maintains PolyPid with a Buy and raises the price target from $11 to $13.
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a
Roth Capital Initiates Coverage On PolyPid with Buy Rating, Announces Price Target of $9
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on PolyPid with a Buy rating and announces Price Target of $9.
أسهم ذات صلة
BCYC
Bicycle Therapeutics plc American Depositary Shares
BBIO
BridgeBio Pharma Inc.
CYTH
Cyclo Therapeutics Inc.
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
XERS
Xeris Biopharma Holdings Inc.
ابق على اطلاع
تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.